About viridian therapeutics inc - VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
VRDN At a Glance
Viridian Therapeutics, Inc.
221 Crescent Street
Waltham, Massachusetts 02453
| Phone | 1-617-272-4600 | Revenue | 70.85M | |
| Industry | Pharmaceuticals: Major | Net Income | -281,928,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 23,359.934% | |
| Fiscal Year-end | 12 / 2026 | Employees | 252 | |
| View SEC Filings |
VRDN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 37.249 |
| Price to Book Ratio | 5.37 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.375 |
| Enterprise Value to Sales | 27.483 |
| Total Debt to Enterprise Value | 0.026 |
VRDN Efficiency
| Revenue/Employee | 281,146.825 |
| Income Per Employee | -1,118,761.905 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.086 |
VRDN Liquidity
| Current Ratio | 12.649 |
| Quick Ratio | 12.649 |
| Cash Ratio | 12.372 |
VRDN Profitability
| Gross Margin | 98.363 |
| Operating Margin | -512.915 |
| Pretax Margin | -483.565 |
| Net Margin | -397.928 |
| Return on Assets | -34.343 |
| Return on Equity | -40.454 |
| Return on Total Capital | -36.479 |
| Return on Invested Capital | -38.454 |
VRDN Capital Structure
| Total Debt to Total Equity | 7.02 |
| Total Debt to Total Capital | 6.559 |
| Total Debt to Total Assets | 5.636 |
| Long-Term Debt to Equity | 8.463 |
| Long-Term Debt to Total Capital | 6.462 |